A Phase 1 study of ESK-001 in participants with renal impairment

Study Description

A study to evaluate the pharmacokinetics of the study drug ESK-001 in people with normal and impaired kidney function

Study Details

Registry ID:

NCT06962774

Conditions:

Renal Impairment

Phase:

Phase 1

Target Enrollment:

16 participants

Start Date:

April 23, 2025

Age Range:

18–75 years

Healthy Volunteers:

No

Study Locations (4 sites)

• Advanced Pharma CR
  Miami, FloridaUnited States, United States
• Panax Clinical Research
  Miami Lakes, FloridaUnited States, United States
• Floridian Clinical Research
  Miami Lakes, FloridaUnited States, United States
• Orlando Clinical Research Center
  Orlando, FloridaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →